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Summary 
Proteomic techniques offer insights into the molecular perturbations occurring in muscular-
dystrophies (MD). Revisiting published datasets can highlight conserved downstream 
molecular alterations, which may be worth re-visiting to determine whether their 
experimental manipulation is capable of modulating disease severity.  
Studying disease models can be useful for identifying biomarkers and model specific 
degenerative cascades, but rarely offer translatable mechanistic insights into disease 
pathology. Conversely, direct analysis of human samples undergoing degeneration presents 
challenges derived from complex chronic degenerative molecular processes. This requires a 
carefully planed & reproducible experimental paradigm accounting for patient selection 
through to grouping by disease severity and ending with proteomic data filtering and 
processing.  
Here, we review the MD literature, highlighting conserved molecular insights warranting 
mechanistic investigation for therapeutic potential. We also describe a workflow currently 
proving effective for efficient identification of biomarkers & therapeutic targets in other 
neurodegenerative conditions, upon which future MD proteomic investigations could be 
modelled. 
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1. Introduction 
The muscular dystrophies (MDs) are a super-family of heritable heterogeneous disorders that 
exhibit similar clinical and pathological features in those affected (1-6). It is estimated that 
muscular dystrophies affect as many as 1 in 6,200 people worldwide and costs exceed $1 
billion per year in the US alone (5). To date, there are upwards of 50 discrete diseases, each 
of which is defined by a distinct genetic mutation and can be inherited as autosomal 
dominant, autosomal recessive, X-linked or, in rare cases, may develop sporadically (2, 5).  
Patients commonly present with progressive weakness in the appendicular, axial and 
maxillofacial muscles but the age of onset, severity of disease and concomitant complications 
vary dramatically between individuals (1, 4-7). The distribution of muscle weakness often 
promotes distinction between the particular types of disease (1). As such, muscular 
dystrophies have been categorised into various groups based upon clinical and molecular 
observations; these include but are not limited to: Duchenne muscular dystrophy (DMD), 
myotonic dystrophy (DM1), facioscapulohumeral muscular dystrophy (FSHD), limb-girdle 
muscular dystrophy (LGMD), Emery-Dreifuss (EDMD) and collagen VI myopathies.  
 
Recent advances in molecular genetics have promoted further understanding of the 
mechanisms governing the varied types of muscular dystrophies. Studies have identified over 
30 causative genes (1-3) that are involved in the pathogenesis of these diseases (DMD: 1; 
FSHD: 2 genes; LGMD: 25 genes; EDMD: 6 genes; collagen VI: 3 genes); most of which 
appear to be protein-coding. Localisation studies of MD related candidates indicate 
perturbations may occur in the skeletal muscle sarcolemma, nuclear membrane, extracellular 
matrix, intermediate filament network and sarcomere (1, 3, 8). Despite this, the functions, 
pathways and downstream targets of these proteins remain to be elucidated. For efficacious 
therapeutic targeting of MDs, it is imperative that research focuses on the downstream 
networks of each particular mutation to assess where intervention may restore cellular 
homeostasis. Proteomic technologies are well equipped to examine such processes and 
various laboratories have begun utilising these techniques for identification of biomarkers 
and novel remedial candidates in MDs. 
 
In this review, we will outline the relative complexities of studying muscular dystrophies and 
how these may be addressed by utilising modern proteomic approaches. We aim to discuss 
the current knowledge concerning the most common muscular dystrophy – DMD and some 
of the less prevalent forms including; DM1, FSHD, LGMD, EDMD and collagen VI 
myopathies.  Here we summarize proteomic derived advancements in our understanding of 
these conditions to date, and where possible and/or appropriate, highlight conserved 
downstream molecular perturbations which may be prove useful as novel biomarkers for 
disease progression and future therapeutic investigations. 
 
2. The Dystrophies 
2.1 Duchenne muscular dystrophy (DMD) 
Duchenne muscular dystrophy (DMD) is the most common dystrophy and (to date) the most 
thoroughly investigated using proteomic methodologies. DMD is a recessive X-linked 
disease, characterized by muscle degeneration and premature death, typically by the age of 
20-30 years. With an incidence of approximately 11-28 per 100,000 males, DMD is one of 
the most common and severe types of muscular dystrophy (8). The cause of DMD is a 
mutation in the dystrophin gene, leading to an absence of the cytoskeletal protein, dystrophin 
(9), and subsequent weakening of the structural integrity of muscle cells. The majority of 
therapeutic approaches for DMD have focused on restoring dystrophin production by 
modulation of RNA using antisense oligonucleotides (10). The development of alternative 
and/or complementary therapeutic strategies to target modifiers of DMD (reviewed by Vo 
and McNally, 2015(11)) or the consequence of downstream pathology (12) appear to be 
emerging areas of research. For work in this area to progress, however, a detailed 
understanding of the molecules and pathways involved in DMD is required.   
 
2.2 Myotonic dystrophy (DM1): Myotonic dystrophy typically manifests in early adulthood 
and is classified as a multi-systemic neuromuscular disease (5, 13) It is the second most 
prevalent dystrophy, but most prevalent adult-onset MD affecting up to 1 in 8000 individuals 
worldwide (14). The disease displays an autosomal dominant mode of inheritance and 
patients often present with highly heterogeneous symptoms including: clinical myotonia, 
progressive muscular weakness, cardiac arrhythmia, visual disturbances and insulin 
resistance (5, 14). These diverse phenotypes are caused by a large expansion of the (CTG)n 
trinucleotide repeat in the 3’ UTR of the dystrophia myotonica protein kinase (DMPK) gene 
on chromosome 19q13.3 (5, 13, 15). Patients with substantial amplifications of these CTG 
repeats demonstrate more severe phenotypes and often present with symptoms at a much 
earlier age, promoting a diminished life-span (14, 15). Broadly speaking, the clinical diversity 
of DM1 phenotypes appears to stem from the sequestration of mutant RNA transcripts 
encoded by the CTG expansion (13, 15). These transcripts accumulate within the nuclei of 
various tissues and promote perturbations in the pathways that regulate alterative splicing 
programmes. Mis-splicing of numerous genes has been experimentally observed in DM1 
patient tissues and mutant cell lines suggesting that patient phenotypes may be attributed to 
the aberrant expression of muscle-specific Cl
-
 channels, cardiac troponin T, insulin receptors 
and the sarcoplasmic Ca
2+
 ATPases (13, 15-17). Although alternative splicing appears to 
demonstrate some involvement within the development and pathogenesis of DM1, there 
remains a lack in understanding of how mechanistic pathways could be therapeutically 
targeted to ameliorate disease progression. 
 
2.3 Facioscapulohumeral muscular dystrophy (FSHD): Facioscapulohumeral muscular 
dystrophy (FSHD) is the third most prevalent of the MDs and is an autosomal dominant 
disease with variable penetrance (18, 19). Typically, as the name suggests, patients present 
with weakness in the maxillofacial muscles and shoulder girdle, which subsequently 
progresses to affect the pelvis and lower extremities (18-20). The onset, progression and 
severity of FSHD are highly variable between and within families and patients can range 
from asymptomatic to critical (19). Unlike other MDs, FSHD usually emerges in adulthood 
with diagnosis typically occurring in the second or third decade (1, 19, 20). However, there 
are reports of patients presenting with early FSHD symptoms in their sixties and seventies 
(18-20), highlighting the heterogeneity of the disease.  
 
The clinical variability of FSHD likely stems from the mutation the patient is harbouring. The 
most common form of the disease, FSHD1, is the result of a contraction of microsatellite 
repeats in the D4Z4 element located on the 4q35 subtelomeric region on chromosome 4 (6, 
18-21). Patients typically present with 1-10 D4Z4 repeats whereas the general population 
demonstrate 11-100 (6, 18-21). Correlations between the repeat size and clinical severity of 
patients have been reported with those harbouring 1-3 copies often more severe than 
individuals with 8-10 copies (18, 19). Evidence suggests that this reduction in D4Z4 copies 
induces chromatin remodelling promoting cellular toxicity and degeneration in skeletal 
muscle (20). Although there are no obvious mutations in any protein-coding gene, it has been 
proposed that there may be erroneous activation of the DUX4, FRG1, FRG2 and ANT1 genes 
that are located centromeric of the D4Z4 array (18, 20). Little is currently known about the 
molecular cascades that are responsible for the clinical manifestation of FSHD due to the 
challenging nature of the disease; thus, the identification of therapeutic targets remains in its 
infancy. Systematic analyses utilising ‘-omics’ data will be invaluable in the field in order to 
establish biomarkers of disease and efficacious treatments for FSHD patients.  
 
2.4 Limb girdle muscular dystrophies (LGMD): Limb girdle muscular dystrophies (LGMD) 
are a group of inherited diseases characterised by progressive weakness and wasting of 
shoulder and pelvic girdle muscles. Broadly, there are two sub-categories of LGMD: those 
which display a dominant manner of inheritance, termed LGMD1 (upwards of 8 subtypes), 
and those which are recessive in nature, LGMD2 (with approximately 20 subtypes) (22). The 
overall frequency of LGMDs is 20-40/100,000 individuals (23) with clinical onset typically 
occurring during the second decade of life (22) The most extensively studied subtypes of the 
disease include LGMD2A, LGMD2B and LGMD1B and the molecular genetics 
underpinning these conditions are now beginning to be unravelled. Recent studies have 
suggested that LGMD2A may be caused by mutations in calpain-3 (24) which promotes the 
loss of autocatalytic function within skeletal muscle, stimulating fibre degeneration and 
atrophy (25). Although there are indications that calpain-3 is involved in the pathophysiology 
of LGMD2A, the function of the protein is still to be established, providing complexities in 
experimental design and interpretation.  
 
LGMD2B is also believed to be caused by mutations in a calcium-handling protein (26). 
Patients presenting with LGMD2B demonstrate mutations in the dysferlin (DYSF) gene (27), 
which encodes a membrane-associated protein localised to the sarcolemma. Dysferlin has 
been noted for its capacity to aid in membrane regeneration and impairments in its function 
appears to stimulate myonecrosis due to increased calcium influx in skeletal muscle. These 
pathological processes are thought to lead to the characteristic shoulder and pelvic girdle 
weakness (28) LGMD1B, like subtypes of EDMD, is caused by mutations in the lamin A/C 
(LMNA) gene (29, 30) Mutations in this gene result in a diverse range of phenotypes often 
with muscular and/or cardiac involvement, however, it is not clear how LMNA contributes to 
these clinical manifestations. Studying the molecular pathways involved downstream of 
LGMD mutations is especially challenging due to the heterogeneity of genetic mutations, 
complex clinical diagnosis and availability of human samples. 
 
2.5 Emery-Dreifuss muscular dystrophy (EDMD): EDMD affects 1 in 100,000 males (31) 
and is characterized by scapulohumeroperoneal muscle weakness, joint contractures and 
cardiac defects that include arrhythmias and dilated cardiomyopathy (32). Onset of EDMD is 
typically seen during childhood or early adolescence (33) and is caused by mutations in 
various genes that are localised to the nuclear envelope (34). Commonly, the disease is X-
linked recessive and is associated with mutations in the emerin (EMD) gene, which 
consequently causes the truncation of emerin proteins (in around two thirds of patients). 
However, multiple subtypes mediated by a range of genetic mutations in the autosomes also 
exist (for more information see Pillers & Bergen, 2016 (35)). As discussed in section 2.4, a 
degree of homology exists between LGMD1B and autosomal dominant EDMD due to both 
subtypes demonstrating mutations in the LMNA gene. Although it is poorly understood how 
mutations in lamin A/C contribute to the LGMD phenotype, EDMD is believed to be caused 
by single amino acid substitutions that result in destabilisation of the protein promoting 
nuclear fragility (36). Less prevalent autosomal dominant forms of the disease have 
demonstrated loss of function mutations in the nesprin-1 (SYNE1 gene) and nesprin-2 
(SYNE2 gene) proteins (OMIM ♯310300) fostering perturbations in nuclear architecture (37). 
 
2.6 Collagen VI myopathies: Collagen VI is a ubiquitously expressed extracellular matrix 
protein (ECM) composed of three folded chains that form dimers and tetramers. In muscle, 
the collagen VI network surrounds the basement membrane transferring mechanical and 
biochemical signals from the ECM to the fibre (38). Mutations in any of these genes can 
cause dysfunction in the microfibrilar network in the ECM of muscle, skin and tendons 
leading to muscle weakness, joint laxity, contractures and respiratory compromise (39). 
Dominant and recessive mutations in collagen VI are often associated with the COL6A1, 
COL6A2 and COL6S3 genes and lead to 2 types of muscular dystrophy: Ullrich congential 
muscular dystrophy (UCMD) and Bethlem myopathy (BM) (40-42). These diseases are 
relatively rare with an estimated prevalence of 0.1 in 100,000 and 0.5 in 100,000 respectively 
(43). UCMD is an autosomal recessive disorder, typically presenting at birth, with infants 
demonstrating hypotonia and congenital hip dislocation. The majority of patients do not reach 
the major motor milestones and struggle to walk independently. Accompanying the motor 
symptoms are severe respiratory problems that require intervention during the first or second 
decade of life (44). Bethlem myopathy is phenotypically milder than UCMD with patients 
demonstrating a near normal life span (42, 45). Despite this, it is estimated that 50% of 
individuals require ambulatory assistance after the age of 50 due to the progressive 
deterioration of muscle and joint integrity (46). For a comprehensive review see Lampe and 
Bushby, 2005 (43). 
 
3. Unravelling downstream dystrophic cascades through proteomic investigations: As 
highlighted in sections 2.1-2.6, there are numerous MD variants aside from the most well 
known DMD, caused by a wide range of associated genetic mutations. There are currently no 
treatments that ameliorate the neuromuscular phenotype and molecular pathology of any of 
these diseases (2). Although several clinical trials for novel therapeutics are in progress, there 
remains a lack of understanding of the basic molecular biology underpinning these diseases. 
To identify efficacious pharmacologic targets, it is imperative that the field utilises modern ‘-
omic’ technologies to examine the pathways and processes that are perturbed and how these 
may regulate downstream pathology. This will facilitate a broader understanding of the 
molecular mechanisms governing muscle development, stability and pathogenesis and will 
ultimately enable data-driven interventions that will benefit patients significantly. 
As many as 50 discrete diseases fall under the umbrella of the dystrophies but at the time of 
writing this manuscript, there are only around 26 published proteomic investigations carried 
out on dystrophy patient or model systems. Of these, 18 studies are focussed on the most 
prevalent and widely known DMD  (supplementary table 1) whilst the remaining 8 surround 
the other less pervasive forms described above (DM1, FSHD, LGMD, EDMD and collagen 
VI myopathies; supplementary table 3).  
3.1 The search for differentially expressed proteins in DMD vs control tissues: To date, 
approximately 19 separate publications from several different research groups have utilized 
unbiased quantitative proteomics technologies to identify differentially expressed proteins in 
models of DMD compared to control subjects. All but one of these studies were conducted 
in-vivo, with diaphragm, cardiac and various skeletal muscles being the most popular tissue 
source. Whilst the vast majority of these studies have utilised the mdx mouse model of DMD, 
material from DMD patients (47, 48) as well as the spontaneous golden retriever muscular 
dystrophy (GRMD) model (49) have also been investigated (summarised in supplementary 
table 1). Though these experiments have generated a wealth of information, there are several 
potential issues that may hamper the translation of findings when the datasets are considered 
in isolation. For these reasons, the focus of discussion in the following section will be on 
proteins that were consistently changed in expression across three or more of the separate 
proteomic comparisons listed in supplementary table 1. This approach also limits the pool of 
useable studies. For example, although Ge et al may have carried out the first of these 
proteomic studies in 2003 we are unable to include their results in our comparative analysis 
as the data sets are not freely available (50). Review of these datasets revealed 34 proteins 
that met these criteria, and are summarised in supplementary table 2.  
 
Increased expression of structural proteins in DMD: The type III intermediate filament 
proteins, desmin and vimentin, were consistently increased across 8 and 15 comparisons of 
DMD tissues, respectively. Considered as a hallmark of developing myotubes (51), the high 
expression of both proteins had previously been documented in regenerating muscle fibres 
from different neuromuscular diseases, including DMD (52, 53). Other structural proteins 
were also consistently increased in DMD tissue across multiple proteomic comparisons, 
including beta-tubulin, lamin A/C, lamin B1 and spectrin alpha chain, as well as proteins 
associated with protein assembly (e.g. elongation protein, Protein disulfide-isomerase A3) 
(supplementary table 2). One possible explanation for this apparent structural reorganisation 
is that it may represent an attempted compensatory response to stabilize the weakened 
cytoskeleton (54). It is interesting to note that increased levels of desmin were also detected 
in a proteomics study of the mildly-affected (and thus, non-regenerating) extraocular muscle 
from the mdx mouse (55), lending support to this notion. The possibility, however, that the 
changes in structural proteins may merely depict the ongoing process of cellular degeneration 
and / or fibrosis must also be considered (56). 
 
Cellular stress responses in DMD: Several proteins associated with a cell stress response 
were elevated in multiple proteomic studies of DMD tissue (supplementary table 2), 
including the heat shock proteins 90, 70, 71 and 78kDa glucose protein (also known as heat 
shock 70 kDa protein 5). Thought to represent a molecular response to cell stress, the 
increased expression of heat shock proteins correlates well with their known involvement in 
dystrophin-deficient muscles (57). 
Increased expression of oxidative stress markers including hemopexin and glutathione-S-
transferase (GST) were detected across several different proteomic studies of DMD 
(supplementary table 2). Glutathione metabolism is clearly dysregulated in dystrophic muscle 
(58, 59), but the cause and functional consequences of this are unclear. While one report has 
proposed a model in which altered glutathione metabolism represents an adaptive and 
attempted compensatory response to oxidative stress (58), others argue that the dysregulation 
of this pathway may actually be the cause of increased oxidative stress in DMD (59, 60). 
Reports of GST activity levels in DMD are also contradictory. While one report demonstrated 
a marked reduction of GST activity in muscle from DMD patients (59), a study of the 
chicken model of DMD demonstrated a reduction of activity (61).  
Though the biochemical studies above detail the differential expression of several key players 
in the glutathione metabolism pathway, as well as the activity of GST, the actual protein 
expression levels of GST have not yet been verified at the biochemical level. Given that 
elevated levels of GST were detected in four separate proteomic studies of DMD 
(supplementary table 2), it would seem there is an opportunity to examine this further and to 
determine whether it is possible to alter the capacity of DMD cells to respond to oxidative 
stress by manipulating GST expression and activity. 
 
Increased membrane permeability in DMD: Increased membrane permeability is a hallmark 
of DMD and though theories exist about what may cause this (reviewed by Allen and 
Whitehead, 2011 (62)), including contraction-induced tears due to fragility of the already-
weakened membrane, oxidative damage to membranes or altered regulation of calcium ion 
channels, the precise mechanisms remain elusive. An increased level of serum albumin was 
detected across 10 separate proteomic comparisons of DMD vs control tissues 
(supplementary table 2), and likely reflects the increased membrane permeability of the target 
tissue (56). Indeed, damage-induced disruption of muscle fibre membranes is commonly 
associated with an influx of extracellular components, containing albumin, into the muscle 
(63), and has previously been detected at the histological level in DMD muscles too (64, 65). 
Parvalbumin, on the other hand, was reduced across eight separate proteomics studies, and 
was one of only two proteins showing a consistent decrease across the multiple proteomic 
comparisons of DMD and control tissues (supplementary table 2). In contrast, a separate 
proteomics-based biomarker discovery project detected increased parvalbumin levels in mdx 
mouse sera (66), possibly indicating that the reduction of parvalbumin in DMD tissues may 
be a result of parvalbumin leaking out into the extracellular space rather than an intra-cellular 
controlled mechanism. Reduced levels of parvalbumin in DMD muscle have also been 
reported previously from biochemical studies (67, 68) and have been implicated in the “Ca2+ 
overload theory”, proposed as a leading mechanism of cellular degeneration in DMD 
(reviewed by Vallejo-Illarramendi et al., 2014 (69)). Potential consequences of Ca
2+
 overload 
were also detected in multiple proteomic comparisons, including an increased expression of 
the Ca
2+ 
-binding protein troponin C (3 comparisons) and increased expression of the Ca
2+ 
-
effector proteins, annexin 2 (8 comparisons) and annexin 5 (6 comparisons) (supplementary 
table 2). Does the influx of albumin, another Ca
2+ 
binding protein, also contribute to Ca
2+
 
overload mechanisms in DMD tissues? 
 
Immune cells may contribute to the proteome of DMD tissues: A prominent feature of 
DMD muscle is the presence of an obvious immune response, though the functional 
consequences of this are still a matter of debate (70). Several types of immune cells have 
been shown to infiltrate mouse and human DMD muscle, including macrophages, 
eosinophils, natural killer T cells, CD4+, and CD8+ T cells (70). Whilst proteomics 
comparisons may have revealed insights into the molecular response to this influx (e.g. 
increased levels of leukocyte elastase inhibitor A (supplementary table 2)), it is important to 
consider that each of these immune cell types could potentially contribute a unique repertoire 
of proteins - quite different from the muscle itself - and would thus skew the proteomic 
profile of the sample. Western blot verification of differential protein expression from total 
protein extracts appears to have been common practice but few studies of this nature have 
also provided histological analysis of the same proteins, meaning that any changes in protein 
expression that are related to tissue heterogeneity would likely be unattributed. 
 
Proteomic insights into the differential vulnerability of muscles in DMD: Of note is that 
there are a large number of proteins (50+) detected across the studies the proteomic 
investigations (summarised in supplementary table 1) that showed contradictory patterns of 
expression in different comparisons (i.e. increased in expression in one or more proteomic 
comparisons but decreased in others). Examples of such proteins are GAPDH, various 
myosin chains, creatine kinase, glycogen phosphorylase, myoglobin and adenylate kinase 
(also identified in (71)). As alluded to previously, changes in the levels of some of these 
proteins could be “false positives”, arising from variations in disease models, tissue 
heterogeneity or tissue sampling techniques. There is also the possibility, however, that some 
of these differences may be useful for determining which constitutive and / or adaptive 
molecular pathways contribute to the differential vulnerability of different muscles in DMD. 
 
Two of the proteomics studies listed in supplementary table 1 specifically aimed to shed light 
on the molecular pathways that determine how vulnerable a particular muscle type is to an 
absence of dystrophin. A 2D-DIGE based quantitative proteomics comparison of the mildly 
affected EOM from mdx and control mice revealed differential expression of just seven 
proteins (55). The authors highlight how these results are a stark contrast to previous 2D-gel 
based comparisons of the severely affected diaphragm muscle, where between 20 and 35 
differentially expressed proteins were detected (72, 73). This suggests that there is a minimal 
perturbation of molecular pathways in the EOM muscle, and perhaps also implies that 
adaptive molecular pathways may not extend far beyond a straightforward upregulation of the 
dystrophin homologue, utrophin (55).  
 
A later study from the same group - in which the proteome of the soleus (SOL), extensor 
digitorum longus (EDL), flexor digitorum brevis (FDB) and interosseous (INT) muscles from 
the mdx mouse were quantitatively compared with control mice - also found differences 
between the number of differentially expressed proteins across different muscle types (74) 
(see supplementary table 1). The histological analysis revealed a higher degree of 
hypertrophy and central nucleation (a hallmark of muscle fibre regeneration) in the SOL and 
EDL muscles compared to INT and FDB.  This clearly does not consistently correlate with 
the degree of differential protein expression, however, since just five proteins were 
differentially expressed in the INT but 19 were differentially expressed in FDB (i.e. more 
than the number detected in the EDL muscle; supplementary table 1). Notwithstanding the 
potential limitations of 2D-gel based quantitative proteomic comparisons, these findings 
serve to highlight the importance of considering results from multiple tissue types before 
drawing generalizable mechanistic conclusions about DMD.   
 
Temporal proteomic studies of DMD: Several proteomic studies aimed to identify temporal 
changes during disease progression in DMD mouse models. These studies provide insights 
into the longer-term secondary molecular changes that occur during disease progression in 
mdx mouse hindlimb muscle (71), cardiac muscle (75), tibialis anterior (76) and diaphragm 
(77).  
Some potentially interesting differences were detected in aged hearts from mdx mice, 
including a reduction of lamin A/C, vimentin and annexin (75), that were both undetected in 
the other aging studies and contrast with findings from various DMD vs control comparisons 
(supplementary table 2). Though the authors were unable to verify the reduction of lamin A/C 
and vimentin by western blot, reduced levels of annexin were confirmed. In addition, while 
the expression level of the developmentally-regulated protein, myosin light chain 2, was 
consistently increased in mdx mouse hindlimb muscle at 1, 3 and 6 months of age compared 
to age-matched controls (71), the levels in aged mdx mouse hearts appear reduced compared 
to controls (75). It is clearly not possible to draw direct comparisons between the various 
studies because of differences in the age of the tissue being compared, but it would be 
interesting in the future to determine whether the differential expression of such candidates 
offers insights into mechanisms underlying the differential vulnerability of muscles in DMD. 
 
3.2 Proteomic insights into other muscular dystrophies:  In recent years, several studies 
utilizing proteomics have appeared in the literature surrounding these less prevalent MDs 
with the aim of enhancing our understanding of the molecular mechanisms underlying the 
downstream effects of the causative mutations. The majority of these investigations have 
employed human patient muscle tissue for comparative characterization of protein expression 
versus controls, in an attempt to distinguish groups of dysregulated proteins in various MD 
subtypes. This has allowed the generation of lists of differentially expressed proteins, 
providing indications of the biological functions and pathways involved in the pathogenesis 
of various MDs. However, there is a requirement for larger numbers of well-executed studies 
to dissect cause/consequence relationships and determine which alterations may reflect 
conserved responses in the range of diseases. 
The complexity of the genetic background of each disease as well as the limited availability 
of human donors provides challenges. Currently there are only seven proteomic-based studies 
focusing on the diseases discussed in section 2 above, most of which have utilized 2D gels, 
followed by mass spectrometry analysis. Selected reports discussed here have attempted to 
discern the commonalities and differences in protein expression between genetic variants of 
particular MDs as well as between diseases using these techniques (see supplementary tables 
3 & 4 for a summary).  
 
Myotonic Dystrophy (DM1):  There is only one readily available publication employing 
proteomic techniques in an attempt to identify the molecular cascades which are perturbed 
downstream of the causative genetic insult in DM1 Hernández-Hernandez and colleagues 
(15) utilised a 2D gel based proteomic analysis on myotonic dystrophy transgenic mice with 
45 kb of human genomic DNA originally cloned from a patient with myotonic dystrophy type 
1 (78, 79). Here they identify potential alterations in post- synapsin I (SYN1) translational 
modifications and elements of RAB3a and its downstream cascades. Various RAB alterations 
have been associated with other neurodegenerative conditions including retinopthaies (80), 
suggesting the possibility of conserved mechanistic cascades across multiple apparently 
unrelated neurodegenerative conditions. However, this study is limited by its choice of 
controls, depth of coverage granted by the use of 2D gels and lacks clarity in terms of 
identification of sample type used for the experiments. 
 
Facioscapulohumeral Muscular Dystrophy (FSHD): At present, there are three proteomic 
studies attempting to address distinct molecular alterations that may be specifically associated 
with FSHD. An early study performed by (18) utilized 2-DE, HPLC-mass spectrometry and 
transcriptomic methods to characterize deltoideus muscle protein expression in groups of 
patients (aged 8-69 years) with varying D4Z4 repeat lengths. The group identified a common 
profile of proteins associated with FSHD, independent of repeat size, suggesting proteins 
associated with glycolysis, the TCA cycle and protein synthesis (particularly elongation 
factor Tu) are upregulated in patient versus control samples; conversely, detoxification and 
degradation proteins (SOD, PRDX2) and actin isoforms are downregulated in FSHD patients. 
Proteins involved in muscle differentiation also appeared to demonstrate differential 
expression between FSHD patient groups and controls: these included COP9, HSP27, alpha-
crystallin B, phosphoglycerate mutase, creatine kinase and myosin heavy chain proteins. 
Upon further analysis, the study identified a conserved upstream regulator – MyoD, levels of 
which were shown to be consistently reduced in patients. The authors hypothesized that 
defects in MyoD signaling promoted the failure of regeneration of fast glycolytic muscle 
fibres after episodes of mechanical stress, leading to a progressive increase in slow oxidative 
fibres, promoting weakness and dystrophy in FSHD patient muscle. 
 
In a similar study by Laoudj-Chenivesse et al (21), 2-DE proteomics coupled with mass 
spectrometry also identified alterations in the detoxification and oxidative stress machinery in 
FSHD patient muscle biopsies. The specimens were obtained from the deltoideus and 
quadriceps muscles and included a range of individuals (aged 17-66 years), all demonstrating 
various D4Z4 repeat lengths. Although there appear to be overlaps in the pathways detected 
between the Laoudj-Chenivesse et al (21) study and the work performed by Celegato et al 
(18), the directionality of the protein expression alterations contrast. For instance, Celegato et 
al (18) report the downregulation of proteins associated with detoxification processes 
whereas Laoudj-Chenivesse et al (21) demonstrate a significant upregulation of these 
cascades (proteins include SOD1 and glutathione-S-transferase). Due to the reported 
upregulation of oxidative stress markers, the Laoudj-Chenivesse et al (21) study focused on 
the potential impact of mitochondrial dysfunction on muscle fibre integrity that was 
hypothesized to be regulated by increased ANT1 expression – a gene neighbouring the D4Z4 
repeat locus. 
 
The final study concerning FSHD has provided another perspective on the molecular 
pathogenesis of the disease. Tassin et al, 2012 (20) utilized patient derived myoblasts (n=2) 
and gel-free shotgun proteomics (2DLC-MS/MS) to characterize atrophic and disorganized 
FSHD myotubes versus control cells. In total, 336 proteins were quantified from the 
quadriceps-derived myoblasts with the study illustrating that myosin heavy and light chain 
(MYH8, MYH3, MYH7; MYL1, MYL6B) and caveolar proteins appeared dysregulated in 
primary FSHD cells. The authors highlighted caveolin-3 (CAV3) and its associated networks 
as potentially perturbed in FSHD promoting the reduction of myogenic differentiation in 
skeletal muscle. CAV3 mutations have previously been documented in other neuromuscular 
diseases, including LGMD1 and LGMD2B, which may suggest that caveolin dysregulation is 
a consequence of myotube degeneration as opposed to an upstream regulator of FSHD.  
 
Molecular overlaps across multiple dystrophies: There is a requirement for further 
comparative studies in order to elucidate how these membrane micro-domains may play a 
role in pathogenesis. One such study by De la Torre et al, 2009 (81) similarly documented an 
impairment in myotube differentiation in LGMD2B patient muscle biopsies. This 
comparative investigation focused on differentially expressed proteins between LGMD2A, 
LGMD2B, FSHD and control triceps and quadriceps muscle using 2-DE and MALDI-TOF 
MS. The authors provided details on 17 conserved proteins that appear altered in all the 
neuromuscular diseases characterized versus the control samples. These proteins displayed 
involvement in energy metabolism, the myofibril and muscle development and repair, 
agreeing with the previously discussed manuscripts studying FSHD. Much like the Celegato 
et al investigation (18), the group show alterations in the muscle fibre distribution with a 
significant increase in slow-twitch fibres. These remodelling events appear to be occurring in 
numerous neuromuscular diseases and track with disease progression. The authors also 
elaborated to include proteins that demonstrated alterations specifically in LGMD2B patients. 
These 14 candidates exhibited similar functional categories to those 17 that were conserved 
through the neuromuscular diseases examined. Although in the De la Torre et al study (81) 
these proteins appeared to demonstrate unique alterations in LGMD2B patients, upon further 
inspection of the literature, there are indications that several of these candidates have been 
discussed in a range of neuromuscular diseases including collagen VI myopathies (de Palma 
et al, 2014 (39)), FSHD (Celegato et al, 2006 (18)) and Duchenne muscular dystrophy. See 
supplementary table 4.  
 
Considerable overlaps exist between investigations examining FSHD and LGMD sub-types, 
which may be due to the upstream regulators of disease or the conserved downstream 
processes of muscle degeneration. Magagnotti et al, 2012 (82) also noted similar pathways 
may be disrupted in EDMD with patients harbouring mutations in the LMNA gene, namely 
LGMD1B. 2-DE proteomics, MALDI-TOF MS and in silico analyses of patient fibroblasts 
suggested that proteins regulating cytoskeletal/structural organisation were less abundant in 
individuals with a diagnosed laminopathy. Conversely, and in keeping with the Laoudj-
Chenivesse et al FSHD study (21), oxidative stress markers appeared enriched in patient cells 
versus controls. Despite Magagnotti et al (82) utilising groups of patients with general 
myopathies as an internal control to assess specific protein alterations in laminopathies, it is 
clear from examination of multiple published datasets that several of these candidates have 
been reported to be differentially expressed in other neuromuscular diseases. See 
supplementary table 4. 
 
Suggestions of skeletal muscle remodelling in MDs are frequently referenced in the literature 
due to the dynamic alterations in proteins involved in myofibrillar architecture and 
cytoskeletal integrity (Celegato et al (18), Tassin et al (20), De la Torre et al (81), Magagnotti 
et al (82) - See supplementary tables 2 & 4). de Palma et al, 2006 (83) also proposed that in 
LGMD2B patients there was a redistribution of muscle fibre type as proteins involved in 
oxidative phosphorylation were increased and those associated with anaerobic metabolism 
decreased, versus control samples. In accordance with the alterations in expression of 
bioenergetic candidates, myosin light chain isoforms were also differentially expressed in the 
LGMD2B patients’ quadriceps muscle, suggesting functional impairments in contractile 
velocity and force may be due to increased numbers of slow-twitch fibres. 
  
A further study conducted by the same authors (de Palma et al, 2014 (39)) focused on the 
collagen VI myopathies: UCMD and BM (see section 2.6). Human quadriceps muscle 
biopsies from BM (n=8), UCMD (n=4) and control (n=2) patients revealed bioenergetics 
pathways were altered in both BM and UCMD individuals versus healthy samples. The 
downregulation of the hexosamine biosynthetic pathway (HBP) was highlighted as a key 
driver of BM and UCMD progression due to associations with protein homeostasis in the 
endoplasmic reticulum and UPR systems. Although this reduction in the HBP and 
glycosylation appeared conserved between the collagen VI MDs, the downstream 
biochemical alterations in UCMD and BM displayed unique properties, likely reflecting the 
differences in disease severity. In BM patient samples, the authors suggest that the muscle 
protein quality control system is sustained by metabolic adaptation. This allows the cells 
energy requirements to be met and the catastrophic consequences of the ER protein mis-
folding response to diminish. In contrast, UCMD patients demonstrate disruption in this 
pathway and the compensatory-layered mechanism, likely leading to lipotoxicity and cellular 
apoptosis. Interestingly, other MDs such as SMA demonstrate perturbations in proteostasis 
with ubiquitin homeostasis defects influencing neuromuscular pathology (84) (see DMD 
section 2.1). 
 
In silico analysis suggests proteomic studies are highlighting downstream consequences of 
degenerative cascades: Although the appearance of common themes in the MD field may 
permit enhanced understanding of the molecular pathology of the various diseases, it may 
also be a great hindrance. The proteomic studies discussed examined groups of 
heterogeneous conditions caused by numerous discrete genetic mutations that all encode for 
different proteins, pathways and processes (see section 2). Thus, the emergence of these 
conserved changes in cytoskeletal and bioenergetic families throughout various 
neuromuscular disorders suggests that these alterations are likely a downstream consequence 
of causal upstream perturbations. Many alterations are likely an adaptive response to ongoing 
myofibril degeneration – a process occurring in all MDs discussed. In fact, with in silico 
analysis of the proteins identified in supplementary table 4, there are clear indications that a 
substantial number of these candidates may be involved in downstream degenerative 
cascades occurring in a wide range of tissues – not merely myofibrils (Figure 1A). 
Alterations in expression of upwards of 15 of these proteins have been associated with 
Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and motor neuron disease in 
published manuscripts (Figure 1B), illustrating likely late-stage consequences of cellular 
dysregulation. Thus, it is probable that these candidates do not represent viable therapeutic 
targets or biomarkers for muscular dystrophies. Despite this, vimentin is consistently 
identified as upregulated throughout the different MD studies. Interestingly vimentin also 
appears to lie upstream of the majority of the candidates identified by the investigations 
reviewed here (Figure 1C). These observations may warrant further analyses into what lies 
further upstream of vimentin and how this may be potentially promoting dysregulation 
selectively within the myofibrillar architecture. However, in order to successfully elucidate 
the upstream regulators of various MDs, there are several considerations that require attention 
before experimentation. Fortunately, the field is now in the position to successfully draw on 
lessons learned form other fields (such as spinal muscular atrophy) where considered 
applications of proteomic techniques have yielded tangible gains (Figure 2).  
 
4. Future directions in dystrophy research through proteomic investigations 
The datasets reviewed in section 3 provide novel and valuable insights into the molecular 
pathways that may be disrupted in muscular dystrophies. The search for conserved and 
unique molecular alterations in muscular dystrophy variants has begun to shed light on the 
downstream pathways affected by these discrete mutations. Despite this, the current studies 
demonstrate some shortcomings in proteomic experimental design and data analysis that 
should be addressed. 
 
Tissue selection and characterisation: The investigations discussed in this review appear to 
focus on static stages of disease in a variety of animal model or pooled patient samples. This 
is a fundamental flaw whilst attempting to elucidate biomarkers of disease progression 
because this approach does not account for the numerous variables that may have influenced 
the data acquired. Primarily, there appears to be an over-simplification of proteomic 
investigations, leading to the loss of potentially relevant information that may indicate how 
MDs are regulated. Commonly the studies report two-way comparisons of pooled samples: 
disease versus control patients; however, the patient cohorts vary significantly. Within the 
MD pooled patient (and animal model) samples, authors include tissues from a variety of 
muscles, ages, clinical severities and genetic mutations – promoting substantial heterogeneity 
and preventing the possibility of also running a variable-matched control sample. It is now 
well established that different tissues and even various anatomical regions of the same tissue 
sample (e.g. proximal versus distal) do not display uniformity in protein expression (85). 
Thus pooling or comparing numerous biopsies from a wide selection of skeletal muscles and 
cellular populations will only hamper the identification of proteins regulating pathogenesis.  
 
In contrast to the majority of studies conducted on other MDs, the vast majority of proteomic 
investigations into DMD have utilized tissue from the mdx mouse and whilst two proteomics 
studies of DMD patients have been conducted, one utilized serum (47) and the other analysed 
urine (48). These sources can certainly be useful for identifying easily accessible biomarkers 
of disease as demonstrated by Coenen-Stass and colleagues (86) innovative identification of 
peripherally accessible biomarkers which demonstrate response to therapeutic attempts in 
mdx mice. However, such peripherally accessible samples do not necessarily offer easily 
translatable mechanistic insights into disease pathology. For example, while one protein may 
appear elevated in the serum of DMD patients, it’s expression in the primary tissue (i.e. 
muscle) could be entirely the opposite. In order to determine that alterations in protein 
expression are due to the presence of disease, the same ages, sexes and clinical severities of 
patients, as well as muscle, and, ideally, the same portion of muscle, must be utilised in the 
pooled MD and control samples. Furthermore, in order to understand disease mechanisms it 
is imperative that protein expression in individuals without the condition is characterised so 
analogous alterations can be eliminated as pathogenic.  
 Characterisation of protein expression profiles throughout disease progression: The 
degenerative process displays complex and dynamic spatio-temporal molecular profiles, 
which demonstrate variability throughout disease progression dependent upon the upstream 
genetic mutation. Fluctuations in protein expression throughout the disease course indicate 
tissue specific cascades, with differing biochemical alterations often occurring in 
neighbouring populations of cells (87). These varying protein expression profiles often reflect 
the vulnerability status of particular cellular clusters that display an enhanced response to 
insult. In order to determine how alterations in protein expression may modulate cellular and 
tissue vulnerability, it is important to track candidate alterations through the time course of 
MDs - from early pre-symptomatic time points to end-stage disease. There is abundant 
evidence to suggest that alterations in causative upstream molecular cascades begin long 
before the onset of detectable pathology (84). From our own studies, we have observed 
significant up/downregulation of numerous proteins during the early stages of disease but at 
later time points protein expression is quite the contrary (87). Therefore, focusing on the early 
stages of disease may provide an enhanced understanding of the molecular mechanisms 
governing muscle degeneration and offer a viable data source for the identification of novel 
drug targets. Additionally a comparison of multiple disease variants (i.e. Duchenne vs Becker 
Kiener dystrophinopathy) with differing severity may also offer more tenable insights into 
potential upstream moderating and/or regulating molecular cascades. 
 
Proteomic techniques: The availability of modern proteomic techniques is beginning to 
direct the field away from 2D gels.  Tools such as label-free proteomics labelled approaches 
including Isobaric Tags for Relative and/or Absolute Quantitation (iTRAQ) or Tandem Mass 
Tagging (TMT) enable a more comprehensive characterization of the molecular alterations 
occurring throughout disease progression. Label free techniques enable comparative analyses 
of multiple samples with low concentrations of protein extracts (87, 88), which may be 
beneficial when working with precious resources such as human patient samples enabling 
analysis with a little as 3-5ug of material for injection into an orbitrap. There are of course 
limitations with the existing tools such as limited dynamic range, compression of ratios 
calculated for tagged samples, and even something as basic as coverage of the proteome 
when compared to more established transcriptomics. Whilst transcriptomics may be ahead of 
proteomics in coverage and usability, it is protein and not RNA which are the ultimate 
effector molecules and the two do not necessarily correlate well (89). Therefore, continued 
developments for the field of proteomics in software, such as Progenesis, allows the 
processing and analysis of complex timecourse profiles and or comparisons, facilitating 
improved methodologies in the MD field. 
 
Data analysis: Filtering and refining of proteomic data is absolutely essential. There remains 
a requirement for laboratories to follow standardised criteria in order to provide more reliable 
and comparable analyses in publications. For example, post-translational modifications 
(PTM) and distinct isoforms should be reported (if known), as they may be a source of 
contradictions in the data shown. If the technique/software/database for the identification of 
protein used is not able to distinguish between protein isoform/PTM, strict filtering should be 
applied to avoid low quality identifications. The re-reporting of published datasets without re-
analysis has the potential to propagate erroneous conclusions throughout published literature 
within the field. Investigators should also utilise available software for in silico analyses. 
These tools enable unbiased comprehension of the pathways and processes that may be 
altered within the samples analysed. It has become increasingly clear that discrepancies exist 
in the data reported by investigators and this affects the outputs from independent pathway 
analyses (see supplementary tables 2 & 4 & Figure 1).  
 
5. Five year perspective on advancements in muscular dystrophy research 
The relatively recent advances in proteomic tools and techniques (as discussed in section 4), 
coupled with the broad range of disparate mutations leading to multiple forms of dystrophy 
with varying prevalence, have (to date) severely impeded a coherent approach to the 
molecular characterisation of the downstream molecular cascades regulating the vulnerability 
of distinct muscle populations and the progression of individual disease variants. We have 
outlined various experimental obstacles in section 4, which require attention before 
conducting proteomic experiments (Figure 2).  
There is clearly scope for future work in this area, using modern approaches such as iTRAQ 
or label-free mass spectrometry, to quantitatively compare the proteome of MD muscles that 
show differential vulnerability. Indeed recent publications examining other 
neurodegenerative conditions such as the childhood motor neurone disease spinal muscular 
atrophy (SMA) have taken a concerted proteomic molecular genetic approach to identify 
regulators pathways and therapeutic targets (84). Here, the authors applied iTRAQ 
proteomics to vulnerable neuronal populations in a SMA murine model to identify 
differentially expressed proteins.  Selected candidates were examined for their ability to 
regulate neuronal stability in multiple small animal model systems including Drosophila and 
Zebrafish before scaling back up to murine systems providing a complete rescue of the 
neuromuscular system. As a result, the authors have published the most effective non-SMN 
replacement therapy to date. The samples and models exist within the dystrophy field to 
allow the replication of such proven target rich workflows to be implemented to inform novel  
(non replacement based) therapeutic interventions for the dystrophies. 
 6. Expert commentary 
Current proteomic studies regarding inherited muscular dystrophies are unravelling 
common/specific disrupted pathways in terms of the molecular constituents altered, but these 
candidates are not necessarily altered in a consistent manner due to the nature of the 
investigations/experimental design employed. Though they provide a window for a better 
understanding of the process of degeneration, some issues should be addressed in future 
work. The development of novel proteomics such as label free techniques, facilitate a more 
complex experimental design where factors such as tissue specific vulnerability and disease 
stages may be taken into account. This will allow researchers to distinguish between early 
and late responses of the specific mutations causing muscular dystrophies and a more 
accurate mapping of the dynamic processes taking place in the muscle. Moreover, the 
production of animal and cellular models that faithfully recapitulate the disease phenotype 
seen in patients will also help for a more comprehensive characterization of the molecular 
changes taking place throughout disease progression than can later be correlated to human 
disease. As there are currently no effective therapeutics for the dystrophies the field is 
reminiscent of where the spinal muscular atrophy field was ten years ago i.e. gene 
replacement therapy is on the extreme horizon, but the tools and techniques are available to 
make some tangible headway into our understanding of the disease processes underpinning 
the condition leading to the identification of novel potential non gene replacement 
therapeutics along the way (84, 87). 
 
7. Key issues 
 Proteomics is a powerful tool for the identification of biomarkers and therapeutic 
targets. 
 Investigators must endeavour to utilise strict and standardised methodologies for 
comparison of control and disease tissues.  
 If identified candidates are enzymes or have a role in metabolic processes, ex vivo 
biochemical or in vivo reporter assays (in model organisms i.e. Drosophila) should be 
performed to determine if detection of altered abundance correlates with altered 
activity/function. 
 Studies should utilise western blotting and immunohistochemical analysis, as well as 
multiple model organisms for validation of candidate relevance to human 
physiological alterations and to assess their ability to moderate disease processes in 
vivo. 
 Such candidates should be assessed for their ability to moderate disease processes in 
vivo and in multiple organsims (i.e. Drosphila/Zebrafish/Rodents) in order to confirm 
relevance in a species/model independent manner. 
 
 
 
Figure & Supplementary Table Legends 
Figure 1. Pathways analysis of conserved overlaps in Muscular Dystrophies. A. Top canonical 
pathways bar chart highlighting the main disrupted cascades in multiple MD subtypes (data from 
supplementary table 4). By combining data from several proteomic studies we are able to identify 
pathways such as multiple Rho-related cascades or “Clathrin-mediated endocytosis signalling” which 
were not specifically reported to be disrupted in these studies. B. Network highlighting how 
candidates identified in multiple MD proteomic studies interact with other neuronal/neuromuscular 
diseases. Alzheimer’s, Parkinson’s, Huntington’s and X-linked hereditary diseases demonstrate 
similar protein expression alterations suggesting these proteins may be involved in downstream 
degenerative cascades. C. Top identified network in IPA generated from MD candidates. Vimentin 
(VIM) appears as a central hub of the network impacting to multiple downstream proteins. Lines in 
blue indicate VIM interactions with other proteins with a conserved change in multiple datasets. B-C. 
All proteins listed in supplementary table 4 were included in the IPA analysis. Candidates with 
reported quantitative values in >2 studies and demonstrating consistent alterations (up-/or down-
regulation) across >50% of these studies were considered for the IPA statistical testing. These proteins 
were assigned an arbitrary fold-change value of +2 or -2 respectively, for the generation of IPA data. 
Red = up-regulation; green = down-regulation; grey = proteins not considered for statistical 
analysis. Dotted lines indicate direct interactions; dashed lines, indirect interactions. 
Figure 2. Experimental design and workflow. Description of the experimental planning and process 
ranging from “Tissue Sampling” to “Validation” of the data produced by proteomic techniques. The 
combination of the selection of specific model/muscle type/time-point of disease progression, high-
throughput proteomic technique, strict data filtering and unbiased bioinformatics analyses followed by 
validation are basic steps to follow. We encourage future proteomic studies to consider this workflow 
in order to produce good quality data to aid in elucidating the mechanisms regulating muscle 
degeneration.  
Supplementary Table 1: Overview of DMD studies employing proteomic screens 
A summary of publications that have utilized unbiased proteomic comparisons of DMD and control 
tissues for the identification of differentially-expressed proteins in DMD models. Studies utilizing 
array-based screens have not been included in this summary. *The number of differentially expressed 
proteins for each study are reported according to the particular criteria used in each study to determine 
differential expression. Abbreviations: VL = vastus lateralis; FDB = flexor digitorum brevis; GM = 
gastrocnemius; SOL = soleus muscle; INT = interosseous; EOM = extraocular muscle; EDL = 
extensor digitorum longus muscle; GRMD = golden retriever muscular dystrophy.  
Supplementary Table 2: Conserved molecular responses in models of Duchenne muscular 
dystrophy 
Individual proteins that were differentially expressed across three or more separate comparisons are 
shown, along with the number of studies they were identified in (“repeat hits”) and the corresponding 
Duchenne model and tissue origin. Proteins that were differentially expressed in one direction in three 
or more studies but in the opposite direction in other studies have been omitted. Abbreviations: VL = 
vastus lateralis; FDB = flexor digitorum brevis; GM = gastrocnemius; SOL = soleus muscle; INT = 
interosseous; EOM = extraocular muscle; GRMD = golden retriever muscular dystrophy. *Also 
increased in SMA across three separate studies (90). 
Supplementary Table 3. Overview of proteomic studies in other Muscular Dystrophies. 
A summary of publications that have utilized unbiased proteomic comparisons of FSHD, LGMD, 
EDMD and collagenVI muscular dystrophies for the identification of differentially-expressed proteins 
vs. control tissues. Studies utilizing array-based screens have not been included in this summary. *The 
number of differentially expressed proteins for each study are reported according to the particular 
criteria used in each study to determine differential expression. 
Supplementary Table 4. Overlapping proteins in all the studies reviewed 
Individual proteins that were differentially expressed (up, down or not reported) across two or more 
separate comparisons are shown, along with the number of studies they were identified in (“repeat 
hits”) and the corresponding tissue of origin, mutation carried and muscle type. Abbreviations: VL = 
vastus lateralis; FDB = flexor digitorum brevis; GM = gastrocnemius; SOL = soleus muscle; INT = 
interosseous;; GRMD = golden retriever muscular dystrophy. 
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